|
|
INTENDED USE
The QuickScreen™ One-Step Rapid Barbiturates Test is a rapid, visual,
qualitative, competitive binding immunoassay for the detection of Barbiturates
in human urine. The test provides a fast confirmation of the
presence of Barbiturates in the subject sample at a minimum cutoff sensitivity
level of 300 ng/ml BAR, the sensitivity level set by the National Institute on
Drug Abuse and Departments of Health and Human Services. Note: Where indicated,
any positive test should be confirmed using quantitative methods by a qualified
testing laboratory. SUMMARY AND EXPLANATION OF THE TEST Barbiturates are a class of prescription drugs frequently abused. Barbiturates in normally prescribed doses act in depressing the central nervous system while overdoses induce exhilaration, sedation, and respiratory depression. Acute overdose results in respiratory collapse, coma, and if not treated promptly, death. Classified generally as depressants, barbiturates produce a state of intoxication that is remarkably similar to alcohol intoxication. Symptoms include slurred speech, loss of motor coordination and impaired judgment. Depending on the dose, frequency, and duration of use, one can rapidly develop tolerance, physical dependence and psychological dependence on barbiturates. Barbiturate abusers prefer the short-acting and intermediate-acting barbiturates pentobarbital (Nembutal), secobarbital (Seconal) and amobarbital (Amytal). Other short-and intermediate-acting barbiturates are butalbital (Fiorinal, Fioricet), butabarbital (Butisol), talbutal (Lotusate) and aprobarbital (Alurate). After oral administration, the onset of drug effect is from 15 to 40 minutes and the effects last up to 6 hours depending on dose administered and body type. Teenagers often abuse barbiturates for the temporary "high" achieved that simulates alcohol intoxication. For comprehensive information on drug testing including typical half-life or drug detection periods see the Drug Testing FAQ. The QuickScreen™ One-Step Rapid Barbiturates Test utilizes a unique combination of monoclonal antibodies to
selectively identify Barbiturates and their metabolites in urine with a high degree of
sensitivity. The test kit is a rapid, visually read screening method that does not require
special instrumentation or training. PRINCIPLE The QuickScreen™ One-Step Rapid Barbiturates Test technology incorporates a chromatographic absorbent device in which the drug or drug metabolites in the sample compete with a Barbiturates derivative immobilized on a porous membrane for limited antibody sites. This is the preferred scientific method for qualitative assay. In the assay procedure, urine mixes with labeled antibody-dye conjugate and migrates through test device. When Barbiturates levels are below 300 ng/ml (the detection cutoff sensitivity of the test) unbound antibody-dye conjugate binds to immobilized antigen conjugate in the Test Zone ("T"), producing a pink-rose colored band that indicates a negative result. Conversely, when Barbiturates levels are above the detection limit, antibody-dye conjugate binds to the free drug, forming an antigen-antibody-dye complex. The complex competes with immobilized antigen conjugate in the Test Zone, preventing the development of a pink-rose colored band. Regardless of the test result, a color band is produced in the Control Zone ("C") by a non-specific sandwich dye conjugate reaction. This band serves as a built-in quality control by demonstrating antibody recognition, verifying that the reagents are chemically active, and confirming that the test was performed correctly. MATERIALS PROVIDED: Test Device and Dropper Pipette individually sealed in foil pouch with complete instructions. ASSAY PROCEDURE
INTERPRETATION OF TEST RESULTS:
Positive One (1) pink-rose band appears in the control zone and no band appears in the test zone. A positive result indicates the Barbiturates level is 300 ng/ml or higher in the test urine sample.
TEST AVAILABILITY
|
|